News

Carl Zeiss Meditec has added new diagnostic tools for dry age-related macular degeneration and glaucoma to the software for its proprietary high-definition ocular coherence tomography (OCT) platform (Cirrus HD-OCT). The new software (Cirrus HD-OCT version 6.0) has received clearance from the FDA.

Preoperative evaluation of patients scheduled to undergo implantation of a refractive IOL is mandatory for obtaining the best postoperative results. Topography, optical coherence tomography of the macula, and fluorescein staining of the cornea are critical when evaluating patients before cataract surgery. William Trattler, MD, in private practice in Miami, described how he manages these patients.

Photocoagulation performed using a micropulse subthreshold diode laser (MicroPulse, Iridex) was superior to intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy, according to a comparative, controlled, prospective study.

The Wills Eye Institute has received institutional review board approval as a site for a phase I/II clinical trial for nonexudative (dry) age-related macular degeneration using human embryonic stem cell-derived retinal pigment epithelial cells from Advanced Cell Technology Inc.

This year’s Operation Eyesight will find the surgeons, physicians, anesthesiologists, and clinic professionals of Minnesota Eye Consultants donating their time and skills to perform eye surgery, at no cost, to patients from Minneapolis and St. Paul, MN, greater Minnesota, and Wisconsin on Feb. 4 and March 10.

Paul P. Lee, MD, JD, has been appointed chairman of the ophthalmology and visual sciences department and holder of the F. Bruce Fralick Professorship at the University of Michigan, Ann Arbor.

Teva UK Ltd. has launched a generic version of latanoprost 0.005% eye drops solution (Xalatan, Pfizer). Latanoprost is indicated for the treatment of elevated IOP in patients who have open-angle glaucoma or ocular hypertension.

Genentech announced it will make its first milestone payment to ForSight VISION4 Inc. as part of an exclusive license agreement to develop an investigational device designed to provide sustained delivery of the vascular endothelial growth factor inhibitor ranibizumab (Lucentis).

The board of directors of ISTA Pharmaceuticals Inc. is reviewing a revised non-binding acquisition proposal from Valeant Pharmaceuticals International Inc.

Results from a prospective randomized eye-to-eye study comparing wavefront-optimized (WFO) and wavefront-guided (WFG) myopic PRK show the WFO technique affords faster visual recovery, but ultimately, quantity and quality of vision appear to be better after WFG PRK, said co-investigators Anthony C. Liu, MD, and Edward Manche, MD.

Analyses of data from baseline structural imaging studies performed in two large prospective, observational glaucoma cohort trials suggest inter-eye asymmetry in optic disc topography parameters and average retinal nerve fiber layer thickness may provide an additional tool to identify eyes with early signs of glaucoma.

The Association for Research in Vision and Ophthalmology is launching a third journal, Translational Vision Science & Technology, an online-only, peer-reviewed journal emphasizing multidisciplinary research that bridges the gap between basic research and clinical care.

Intraoperative application of a proprietary in situ gel-forming hydrogel to the sutured conjunctival-limbal incision is safe and shows promise as an effective "bandage" for preventing early postoperative wound leaks in eyes undergoing fornix-based trabeculectomy surgery.

The field of laser cataract surgery continues to evolve with the Dec. 22 announcement by OptiMedica that its proprietary laser system received FDA 510(k) market clearance for capsulotomy and lens fragmentation.

Genetic research has identified genes that can cause glaucoma primarily on their own and genes that require involvement of multiple genes and environmental factors in order for the disease to develop.

Gregory Hageman, PhD, has been selected for the 2011 Lighthouse International Pisart Vision Award. Presented annually, this award honors an individual who has “distinguished himself or herself by invention or otherwise in the prevention, cure, treatment, or care of blindness.”

Quark Pharmaceuticals Inc. has announced favorable interim results from the first two cohorts of its open-label, first-in-human phase I clinical study of QPI-1007, its proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy.

Data from a large European study link daily aspirin use to increased risk of age-related macular degeneration (AMD). Researchers found that people aged 65 and older who took aspirin daily had double the risk of developing wet AMD, compared with those who took it less frequently.